Deadly virus detected post-Cyclone Alfred
Japanese encephalitis virus (JEV) was detected in Hemmant, a suburb in Brisbane's east, on Friday. It can cause severe neurological illness and even death, according to Queensland Health.
The health authority said routine mosquito surveillance programs detected the presence of JEV in Brisbane, adding the risk of human exposure could increase after recent flooding following Ex-Tropical Cyclone Alfred.
Queensland Health's chief health officer Dr Heidi Carroll said the Brisbane detection meant JEV increased mosquito surveillance is underway as a result of the increased risk of infection across a number of regions in Queensland.
'This latest detection is the first for Brisbane and tells us that more mosquito populations are likely carrying the virus. It's critical that Queenslanders remain extra vigilant against mosquito bites across the state, no matter where they live,' Dr Carroll said.
'While most people infected with JEV experience only mild symptoms or no symptoms at all, those who do develop more serious symptoms may experience fever, headache, abdominal pain or vomiting, typically within five to 15 days of being bitten.'
Dr Carroll said it is 'common' to see mosquito populations increase after wet and warm weather, which increases the risk of contracting mosquito-borne illness. She urged residents to focus on prevention measures to avoid getting infected by the virus.
'I encourage all Queenslanders to adopt personal protective measures to avoid mosquito bites such as using repellents containing DEET, picaridin or oil of lemon eucalyptus, wearing long, loose-fitting, light-coloured clothing, and using mosquito coils (outdoors) and insecticide vaporisers,' she said.
'Pooled water makes ideal conditions for mosquitoes to breed, so it's important that everyone makes sure to, wherever possible, remove standing water around their home following recent rain and flooding.'
Queensland recorded its first locally-acquired human case of JEV since 2022 in January this year. This case is likely to have been infected in the Darling Downs region, near Goondiwindi.
JEV has been detected in mosquito populations in the Darling Downs and Wide Bay regions, as well as in mosquito and feral animal populations in other parts of the state.
'Mosquitoes become infected with JEV after they bite infected pigs or wading birds. JEV can then be spread to humans through the bite of an infected mosquito,' Dr Carroll said.
'Piggery workers are at risk of exposure to JEV due to their work. It's very important if you work at, live near or have a planned visit to a piggery, to take advantage of free vaccination against JEV. Transport workers, veterinarians or others involved in the care of pigs are also eligible.'
The JEV vaccination is available at selected GPs, pharmacies and community immunisation providers. The vaccine itself is free for eligible Queenslanders.
The detection comes after NSW authorities urged residents to take steps to avoid being bitten following the death of a man in his 70s last week.
NSW Health said the man likely acquired JEV while on a holiday in the Murrumbidgee region and marked the second death in the state this year.
'People need to take mosquito-borne infections seriously, especially as people start the clean-up from recent floods in an environment where mosquitos thrive,' NSW Health's Executive Director of Health Protection Dr Jeremy McAnulty said.
'Standing water, like that left after mass rainfall and floods, makes for ideal breeding grounds for mosquitoes.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 million Tiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit royalties elsewhere Kowa will assume full responsibility for the preparation and filing costs of the U.S. NDA for NCX 470, and all future development and commercial costs Provides flexibility for Nicox to explore future growth options July 17, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced the signing of a major new agreement concerning NCX 470 with Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-breaking research, development and marketing. The agreement, worth up to €191.5 million, grants Kowa exclusive rights to develop and commercialize NCX 470, Nicox's nitric oxide (NO)-donating bimatoprost eye drop, for the lowering of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension in the U.S. and all other territories of the world excluding Japan, China, Korea and Southeast Asia. Kowa already has a license to NCX 470 for Japan, where it is preparing to enter a Phase 3 clinical trial. NCX 470 is also licensed to Ocumension Therapeutics for China, Korea and Southeast the terms of the agreement, Nicox will receive an upfront payment of €7.5 million on signing. Additional near-term milestones payments are due on positive topline results from the Denali clinical trial, expected mid-August to mid-September 2025, and on submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), which is currently expected in H2 2026. The total potential development and sales milestones payments will be either €127 million or €191.5 million, depending on the outcome of the Denali clinical trial, plus royalties up to 20% in the U.S. 'This new agreement with our existing partner, Kowa, is a major endorsement of NCX 470's potential in glaucoma and marks a major step forward in strengthening Nicox's financial position. With NCX 470 now globally licensed, we are focused on delivering the Denali Phase 3 results, which we anticipate releasing mid-August to mid-September.' said Gavin Spencer, Chief Executive Officer of Nicox. 'The revenue stream we expect from NCX 470 gives us the flexibility to pursue future growth opportunities, leveraging our expert U.S. ophthalmology development team.''Expanding our collaboration with Kowa, who now becomes our key commercial partner for NCX 470 in the U.S and other major territories, is based on a very successful history of working together. We believe that Kowa has recognised the significant market potential of NCX 470, which we expect to be confirmed with the upcoming results from the Denali Phase 3 trial.' said Emmet Purtill, VP Business Development of Nicox. 'We look forward to continuing to work with Kowa as well as our partner for the Chinese market, Ocumension, to bring NCX 470 to glaucoma patients worldwide.' Details of the AgreementUnder the terms of the exclusive licensing agreement, Kowa is granted rights to develop and commercialize NCX 470 worldwide, excluding the territories already licensed to Ocumension (China, Korea and Southeast Asia) and to Kowa itself (Japan). The collaboration will be managed by a Joint Steering Committee. Key terms include:Milestone PaymentsNicox will receive an upfront payment of €7.5 million upon signing the agreement. Additional near-term milestones payments are due on positive topline results from the Denali Phase 3 clinical trial, expected mid-August to mid-September 2025 and upon submission of an NDA to the FDA, which is currently expected in H2 2026. The total potential development and sales milestones payments will be either €127 million or €191.5 million, depending on the outcome of the Denali clinical trial. Royalty PaymentsKowa will pay Nicox tiered royalties in the U.S. which could reach 20% of net sales. Depending on the results of the Denali clinical trial, royalties due in the U.S. will initially be 8% or 10%. Outside of the U.S., Nicox will receive tiered royalties ranging from single-digit to double-digit percentages. Nicox ObligationsNicox is responsible, at its cost, for generating the remaining development data necessary for the NDA submission to the FDA (principally pharmacokinetic studies) and will support Kowa in preparation of the ObligationsOther than the activities for which Nicox is responsible, Kowa is responsible, at its cost, for all development, regulatory and commercialization activities for NCX 470 in the licensed Runway and Debt RepaymentAs disclosed in the amended bond agreement announced on 14 October 2024, 70% of the upfront payment from Kowa will be used to partially reimburse Nicox's debt, reducing the total debt to €9.6 million. Based on the current cash position (estimated1 at €5.9 million as of 30 June 2025) expected revenue and anticipated milestone payments, Nicox forecasts that it has over 12 months of cash at the date of signature of this agreement. Glaucoma Pharmaceutical MarketThe glaucoma pharmaceutical market is estimated at over $7 billion2, with the U.S. market accounting for around 40%, growing globally at around 3% to 5% CAGR and the number of patients globally is estimated to be around 80 million3. About NCX 470NCX 470, Nicox's lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development in the U.S., China and Japan (clinical trial authorisation granted for Japan) for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the Phase 3 clinical trials, have been extensively published and are available on our website. The second Phase 3 clinical trial, Denali, is currently ongoing. The last patient in Denali has completed their final visit, and the results are expected mid-August to mid-September 2025. Mont Blanc and Denali have been designed to fulfil the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China. All remaining NDA-enabling pharmacokinetic and non-clinical studies necessary to support the U.S. NDA filing are on track. A separate Phase 3 program is underway to support Japanese approval, with the first patient expected to be enrolled in H2 2025. NCX 470 is exclusively licensed to Ocumension Therapeutics in China, Korea and Southeast Asia, and to Kowa in the rest of the world. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa elsewhere. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@ Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking factors which are likely to have a material effect on Nicox's business are presented in section 3 of the 'Rapport Annuel 2024' which is available on Nicox's website ( this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 1 Non-audited figure 2 Antiglaucoma Drug Market Size, Trends, Growth Report 2034; Glaucoma Therapeutics Market Report by Drug Class (Prostaglandin Analogs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others), Indication (Open Angle Glaucoma, Angle Closure Glaucoma, and Others); Glaucoma Therapeutics Market Size, Growth, Analysis - 20313 World Glaucoma Association website: World Glaucoma Association » What is glaucoma? Attachment EN_NCX470KowaGlobalLicenseJuly2025_PR_FINALError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 hours ago
- Yahoo
I tried this power walking method to boost my heart rate and reduce my stress levels — and I'm hooked
When you buy through links on our articles, Future and its syndication partners may earn a commission. Power walking has been around long before TikTok made it cool. It's been found to be good for your bones, reduce your risk of high blood pressure, burn calories, and improve your mental health. Unlike running or jogging, walking has a low impact on your joints, so it is suitable for most people, plus you don't need any fancy equipment to get a good workout — just a comfortable pair of sneakers will do. How to power walk Power walking, also known as brisk walking, is exactly what it sounds like — you're walking at a faster pace, probably an effort of six or seven out of ten. An easy way to tell if you're walking quickly enough is the talk test — imagine you're walking with a friend, at the right pace you'd be able to hold a conversation, but you'd probably be a little breathless. If you couldn't speak without gasping for breath, you're walking too fast. If you could easily talk like you would standing still, you're not walking quickly enough. If you couldn't speak without gasping for breath, you're walking too fast. If you could easily talk like you would standing still, you're not walking quickly enough. Alternatively, if you have one of the best fitness trackers strapped to your wrist, another way to check your pace is by looking at your heart rate. When power walking, your heart rate should be 50 to 85 per cent of your maximum heart rate. Your maximum heart rate is 220 beats per minute (bpm) minus your age in years. Therefore, for a 30-year-old, the calculation would be 220 - 30 = 190 bpm. To determine the range you should be walking in, multiply this number by 0.5 to find 50 percent of your maximum heart rate (so 95 bpm for a 30-year-old), and by 0.85 to see 85 percent (162 bpm). Keep an eye on your heart rate as you walk and try and keep it in this zone. What are the benefits of power walking? We've explored the effects of 30 minutes of power walking on the body in more detail here, but in simple terms, power walking is an excellent form of cardio. You're working your entire body as you walk — just make sure you think bout engaging your core to stabilize your torso, and swinging your arms as you walk. Not only does power walking raise your heart rate and burn calories, but studies have found this form of walking can reduce your blood pressure and your risk of high cholesterol and diabetes. I tried this power walking method to boost my heart rate and reduce my stress levels — and I'm hooked As Tom's Guide's fitness editor, I'm no stranger to a walking challenge — you can read what happened when I tried the Japanese walking method for a week here, as well as when I took on the 12-3-30 walking workout for a month. Yet next on my list was a 20-minute power walking workout, with a five-minute warm-up and cool down. As always, I set up the workout on my Apple Watch 10 beforehand — here's how to build a workout on your Apple Watch. During the power walking workout itself, I used the 1-2 step method — this refers to a technique where you swing your arms in a 1-2 rhythm to match your steps. I found myself counting 'one, two' throughout the workout, focusing on swinging my arms, with a 90-degree bend in my elbow, as I took a big step forward each time, striking the floor with my heel and rolling to the ball of my foot. I found the counting and the arm swing helped me take longer strides, working my lower body harder as I pushed myself forward. Unlike going for a run, I wasn't immediately out of breath, but I found myself working hard as my heart rate increased. I focused on my form, keeping my core engaged and my torso upright. I tend to tense through my head and neck as I push myself, so I thought about keeping my neck, shoulders, and back relaxed. My heart rate remained elevated throughout the 20-minute workout, but stayed at 50-60% of my maximum heart rate. More importantly, I really enjoyed the power walking session. While it won't be for everyone, the 1-2 rhythm was somewhat meditative, and I found myself tuning into my body and focusing on my walk. I use exercise as a way to reduce stress and improve my mental health, and this workout did just that. If 20 minutes of brisk walking is too ambitious, why not mix intervals of brisk walking with intervals of slower walking to recover? The Japanese walking method involves three minutes of a brisk walk, followed by three minutes of a slower-paced walk to recover. Remember, your brisk walking pace will be different from mine, and that the best workout for you is the one you enjoy the most. As always, if you're new to exercise or you're returning to workouts following an injury or pregnancy, it's always a good idea to check in with a doctor before taking on a new workout routine. More from Tom's Guide Forget running — 3 walking workouts that build lower body strength and burn calories I tried this 3-2-1 walking workout — and it boosted my energy level and my mood Walking for weight loss: what you need to know
Yahoo
20 hours ago
- Yahoo
Footballer's career ended prematurely because of unnecessary procedure
A former Premier League footballer's career came to a 'premature end' due to an unnecessary procedure carried out by a leading surgeon, the High Court has been told. Ex-Wolverhampton Wanderers striker Sylvan Ebanks-Blake, 39, had surgery after he broke his left leg during a match against Birmingham City in April 2013. He alleges that during the operation to fix his leg, the surgeon, Professor James Calder, also performed procedures, which included cleaning out the joint and removing some cartilage, that 'gave rise to inflammation', and sped up the development of osteoarthritis in his ankle. He also says the surgeon failed to properly tell him the risks associated with the procedure. Prof Calder is defending the claims and denies that there was a lack of time for the footballer to weigh up his options. In written submissions, Simeon Maskrey KC, representing Ebanks-Blake, said on Wednesday: 'The onset of symptoms and the development and acceleration of osteoarthritis brought the claimant's footballing career to a premature end.' Mr Maskrey said the footballer had suffered a previous ankle injury and, although this resulted in some 'stiffness', he had learned to adapt and it caused him no pain. He continued: 'The proposed procedure carried with it the significant risk that it would render the ankle symptomatic.' Mr Maskrey also told the court the surgery consent process was 'wholly inadequate', and Ebanks-Blake was given 'no opportunity of considering his options'. He added that had his client been told that 'wait and see' was a reasonable option, which ran the risk of the ankle becoming symptomatic and needing later intervention, 'he would have taken that risk'. Mr Maskrey said it was for the court to decide whether Ebanks-Blake 'was provided with sufficient information to provide informed consent'. Martin Forde KC, representing the surgeon, said in written submissions: 'It is arguable that if Professor Calder had done anything other than what he did do, he would have been negligent for not dealing with the loose fragments and unstable cartilage.' He continued: 'The defendant's position is that through his judgment and skill he prolonged the claimant's career. 'The claimant's case quite clearly is that his career was curtailed.' Mr Forde also told the court that Ebanks-Blake's witness statement is the earliest indication of his 'dissatisfaction', and before this, he had made positive comments about his recovery from injury. He added: 'Far from curtailing the claimant's career, the defendant will argue that his clinical skills prolonged the career of a professional player who suffered a very serious injury.' Mr Forde told the court that after the surgery, Ebanks-Blake continued playing football for a number of years, retiring in 2019. The case before Mrs Justice Lambert is due to conclude on Tuesday July 22.
